Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luigi Scaffidi

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Cancer Medicine|October 8, 2022
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the "GRUPPO TRIVENETO LMC"Sara Di Giusto, Eleonora Toffoletti, Massimiliano Bonifacio, et al.
Cancer Medicine|August 31, 2021
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general populationMassimiliano Bonifacio, Mario Tiribelli, Maria Cristina Miggiano, et al.
Cancer Medicine|April 6, 2019
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuationSimona Bernardi, Michele Malagola, Camilla Zanaglio, et al.
Leukemia Research|October 12, 2018
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in ItalyMassimiliano Bonifacio, Luigi Scaffidi, Gianni Binotto, et al.
Oncotarget|March 28, 2018
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patientsMario Tiribelli, Massimiliano Bonifacio, Gianni Binotto, et al.
Hematological Oncology|May 18, 2017
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent studyFrancesca Palandri, Mario Tiribelli, Giulia Benevolo, et al.
International Journal of Cardiology|April 29, 2019
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary preventionGiovanni Caocci, Olga Mulas, Massimiliano Bonifacio, et al.
Annals of Hematology|November 27, 2023
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinibOlga Mulas, Elisabetta Abruzzese, Luigiana Luciano, et al.
Hematological Oncology|February 22, 2021
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitorsRoberto Latagliata, Immacolata Attolico, Malgorzata Monika Trawinska, et al.
Hematological Oncology|March 21, 2019
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chartGiovanni Caocci, Olga Mulas, Elisabetta Abruzzese, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Cancer Medicine|October 8, 2022
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the "GRUPPO TRIVENETO LMC"Sara Di Giusto, Eleonora Toffoletti, Massimiliano Bonifacio, et al.
Cancer Medicine|August 31, 2021
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general populationMassimiliano Bonifacio, Mario Tiribelli, Maria Cristina Miggiano, et al.
Cancer Medicine|April 6, 2019
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuationSimona Bernardi, Michele Malagola, Camilla Zanaglio, et al.
Leukemia Research|October 12, 2018
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in ItalyMassimiliano Bonifacio, Luigi Scaffidi, Gianni Binotto, et al.
Oncotarget|March 28, 2018
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patientsMario Tiribelli, Massimiliano Bonifacio, Gianni Binotto, et al.
Hematological Oncology|May 18, 2017
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent studyFrancesca Palandri, Mario Tiribelli, Giulia Benevolo, et al.
International Journal of Cardiology|April 29, 2019
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary preventionGiovanni Caocci, Olga Mulas, Massimiliano Bonifacio, et al.
Annals of Hematology|November 27, 2023
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinibOlga Mulas, Elisabetta Abruzzese, Luigiana Luciano, et al.
Hematological Oncology|February 22, 2021
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitorsRoberto Latagliata, Immacolata Attolico, Malgorzata Monika Trawinska, et al.
Hematological Oncology|March 21, 2019
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chartGiovanni Caocci, Olga Mulas, Elisabetta Abruzzese, et al.
Pageof 5